Ikena Oncology (IKNA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

IKNA Stock Forecast

Ikena Oncology stock forecast is as follows: an average price target of $1.33 (represents a -21.76% downside from IKNA’s last price of $1.70) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

IKNA Price Target

The average price target for Ikena Oncology (IKNA) is $1.33 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $1.33 to $1.33. This represents a potential -21.76% downside from IKNA's last price of $1.70.

IKNA Analyst Ratings

Buy

According to 6 Wall Street analysts, Ikena Oncology's rating consensus is 'Buy'. The analyst rating breakdown for IKNA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 1 'Hold' (16.67%), 1 'Sell' (16.67%), and 0 'Strong Sell' (0.00%).

Ikena Oncology Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 29, 2024	David Nierengarten	Wedbush	$1.33	$1.64	-18.90%	-21.76%
May 29, 2024	David Nierengarten	Wedbush	$2.00	$1.33	50.38%	17.65%

Row per page

Go to

The latest Ikena Oncology stock forecast, released on May 29, 2024 by David Nierengarten from Wedbush, set a price target of $1.33, which represents a -18.90% decrease from the stock price at the time of the forecast ($1.64), and a -21.76% decrease from IKNA last price ($1.70).

Ikena Oncology Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$1.67
Last Closing Price	$1.70	$1.70	$1.70
Upside/Downside	-100.00%	-100.00%	-1.76%

In the current month, the average price target of Ikena Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ikena Oncology's last price of $1.70. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
May 29, 2024	William Blair	Outperform	Outperform	Hold
May 29, 2024	Cowen & Co.	Buy	Buy	Hold
May 29, 2024	Wells Fargo	-	Underweight	Downgrade
May 29, 2024	Wedbush	Outperform	Neutral	Downgrade
May 29, 2024	H.C. Wainwright	Buy	Buy	Hold
May 14, 2024	Wedbush	Buy	Outperform	Initialise
Mar 19, 2024	Wedbush	Buy	Buy	Hold
Mar 19, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Jan 19, 2024	Wedbush	Outperform	Outperform	Hold
Sep 22, 2023	Wedbush	-	Outperform	Initialise

Row per page

Go to

Ikena Oncology's last stock rating was published by William Blair on May 29, 2024. The company gave IKNA a "Outperform" rating, the same as its previous rate.

Ikena Oncology Financial Forecast

Ikena Oncology Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$659.00K	-	-	$5.31M	$5.45M	$6.40M	$382.00K	$3.38M	$20.22M	$3.75M	$3.55M	$3.47M
Avg Forecast	-	-	-	-	$1.25M	$1.25M	$1.25M	$1.25M	$1.25M	$1.25M	$875.00K	$2.33M	$2.44M	$2.84M	$3.85M	$4.61M	$6.02M	$4.32M	$3.87M	$4.57M	$4.79M	$4.05M	$3.93M	$3.97M
High Forecast	-	-	-	-	$1.25M	$1.25M	$1.25M	$1.25M	$1.25M	$1.25M	$875.00K	$2.33M	$5.10M	$2.84M	$3.85M	$4.61M	$6.02M	$4.32M	$3.87M	$4.57M	$4.79M	$4.05M	$3.93M	$3.97M
Low Forecast	-	-	-	-	$1.25M	$1.25M	$1.25M	$1.25M	$1.25M	$1.25M	$875.00K	$2.33M	$673.39K	$2.84M	$3.85M	$4.61M	$6.02M	$4.32M	$3.87M	$4.57M	$4.79M	$4.05M	$3.93M	$3.97M
# Analysts	-	-	-	-	1	1	1	1	1	3	1	2	4	2	2	2	1	1	1	1	2	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.27%	-	-	1.15%	0.91%	1.48%	0.10%	0.74%	4.22%	0.92%	0.90%	0.88%

Ikena Oncology's average Quarter revenue forecast for Mar 24 based on 2 analysts is $2.33M, with a low forecast of $2.33M, and a high forecast of $2.33M. IKNA's average Quarter revenue forecast represents a 254.07% increase compared to the company's last Quarter revenue of $659.00K (Dec 23).

Ikena Oncology EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	1	1	1	1	1	3	1	2	4	2	2	2	1	1	1	1	2	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-21.60M	$-19.50M	$-18.49M	$-15.28M	$-14.90M	$-17.66M	$-20.80M	$-16.78M	$2.96M	$-14.94M	$-11.97M	$-9.63M
Avg Forecast	-	-	-	-	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-875.00K	$-2.33M	$-2.44M	$-2.84M	$-3.85M	$-4.61M	$-6.02M	$-4.32M	$-3.87M	$-14.52M	$-4.79M	$-4.05M	$-3.93M	$-14.78M
High Forecast	-	-	-	-	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-875.00K	$-2.33M	$-673.39K	$-2.84M	$-3.85M	$-4.61M	$-6.02M	$-4.32M	$-3.87M	$-11.62M	$-4.79M	$-4.05M	$-3.93M	$-11.82M
Low Forecast	-	-	-	-	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-1.25M	$-875.00K	$-2.33M	$-5.10M	$-2.84M	$-3.85M	$-4.61M	$-6.02M	$-4.32M	$-3.87M	$-17.43M	$-4.79M	$-4.05M	$-3.93M	$-17.74M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	8.86%	6.87%	4.80%	3.31%	2.48%	4.08%	5.37%	1.16%	-0.62%	3.69%	3.04%	0.65%

1 analysts predict IKNA's average Quarter EBITDA for Mar 22 to be $-14.52M, with a high of $-11.62M and a low of $-17.43M. This is -590.68% lower than Ikena Oncology's previous annual EBITDA (Dec 21) of $2.96M.

Ikena Oncology Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	1	1	1	1	1	3	1	2	4	2	2	2	1	1	1	1	2	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-19.49M	$-17.34M	$-17.11M	$-12.92M	$-13.08M	$-16.80M	$-20.03M	$-16.72M	$2.80M	$-14.52M	$-12.68M	$-9.72M
Avg Forecast	$-6.04M	$-6.03M	$-6.01M	$-6.77M	$-8.69M	$-8.85M	$-8.85M	$-9.97M	$-9.97M	$-12.30M	$-16.72M	$-19.19M	$-20.09M	$-20.78M	$-22.87M	$-22.52M	$-7.04M	$-23.81M	$-23.56M	$-14.83M	$-24.72M	$-20.27M	$-17.25M	$-14.92M
High Forecast	$-6.04M	$-6.03M	$-6.01M	$-6.77M	$-8.69M	$-8.85M	$-8.85M	$-9.45M	$-9.45M	$-12.30M	$-16.72M	$-19.19M	$-16.82M	$-20.78M	$-22.87M	$-22.52M	$-7.04M	$-23.81M	$-23.56M	$-11.87M	$-24.72M	$-20.27M	$-17.25M	$-11.93M
Low Forecast	$-6.04M	$-6.03M	$-6.01M	$-6.77M	$-8.69M	$-8.85M	$-8.85M	$-10.50M	$-10.50M	$-12.30M	$-16.72M	$-19.19M	$-26.62M	$-20.78M	$-22.87M	$-22.52M	$-7.04M	$-23.81M	$-23.56M	$-17.80M	$-24.72M	$-20.27M	$-17.25M	$-17.90M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.97%	0.83%	0.75%	0.57%	1.86%	0.71%	0.85%	1.13%	-0.11%	0.72%	0.74%	0.65%

Ikena Oncology's average Quarter net income forecast for Mar 22 is $-14.83M, with a range of $-17.80M to $-11.87M. IKNA's average Quarter net income forecast represents a -630.37% decrease compared to the company's last Quarter net income of $2.80M (Dec 21).

Ikena Oncology SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	1	1	1	1	1	3	1	2	4	2	2	2	1	1	1	1	2	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$8.29M	$6.03M	$5.32M	$5.28M	$4.92M	$5.43M	$5.84M	$6.00M	$5.09M	$4.89M	$4.86M	$3.17M
Avg Forecast	-	-	-	-	$1.55M	$1.55M	$1.55M	$1.55M	$1.55M	$1.55M	$1.09M	$2.90M	$3.03M	$3.53M	$4.79M	$5.74M	$7.48M	$5.38M	$4.82M	$5.68M	$5.95M	$5.04M	$4.89M	$4.93M
High Forecast	-	-	-	-	$1.55M	$1.55M	$1.55M	$1.55M	$1.55M	$1.55M	$1.09M	$2.90M	$6.35M	$3.53M	$4.79M	$5.74M	$7.48M	$5.38M	$4.82M	$5.68M	$5.95M	$5.04M	$4.89M	$4.93M
Low Forecast	-	-	-	-	$1.55M	$1.55M	$1.55M	$1.55M	$1.55M	$1.55M	$1.09M	$2.90M	$837.65K	$3.53M	$4.79M	$5.74M	$7.48M	$5.38M	$4.82M	$5.68M	$5.95M	$5.04M	$4.89M	$4.93M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	2.73%	1.71%	1.11%	0.92%	0.66%	1.01%	1.21%	1.06%	0.85%	0.97%	0.99%	0.64%

Ikena Oncology's average Quarter SG&A projection for Mar 24 is $2.90M, based on 2 Wall Street analysts, with a range of $2.90M to $2.90M. The forecast indicates a -65.00% fall compared to IKNA last annual SG&A of $8.29M (Dec 23).

Ikena Oncology EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	1	1	1	1	1	3	1	2	4	2	2	2	1	1	1	1	2	2	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.41	$-0.00	$-0.44	$-0.36	$-0.36	$-0.46	$-0.55	$-0.46	$0.08	$-0.40	$-0.35	$-2.52
Avg Forecast	$-0.13	$-0.12	$-0.12	$-0.14	$-0.18	$-0.18	$-0.18	$-0.21	$-0.21	$-0.25	$-0.35	$-0.40	$-0.42	$-0.43	$-0.47	$-0.47	$-0.15	$-0.49	$-0.49	$-0.42	$-0.51	$-0.42	$-0.36	$-0.87
High Forecast	$-0.13	$-0.12	$-0.12	$-0.14	$-0.18	$-0.18	$-0.18	$-0.20	$-0.20	$-0.25	$-0.35	$-0.40	$-0.35	$-0.43	$-0.47	$-0.47	$-0.15	$-0.49	$-0.49	$-0.42	$-0.51	$-0.42	$-0.36	$-0.87
Low Forecast	$-0.13	$-0.12	$-0.12	$-0.14	$-0.18	$-0.18	$-0.18	$-0.22	$-0.22	$-0.25	$-0.35	$-0.40	$-0.55	$-0.43	$-0.47	$-0.47	$-0.15	$-0.49	$-0.49	$-0.42	$-0.51	$-0.42	$-0.36	$-0.87
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.99%	0.00%	0.93%	0.77%	2.47%	0.93%	1.13%	1.10%	-0.15%	0.95%	0.98%	2.89%

According to 1 Wall Street analysts, Ikena Oncology's projected average Quarter EPS for Mar 22 is $-0.42, with a low estimate of $-0.42 and a high estimate of $-0.42. This represents a -636.05% decrease compared to IKNA previous annual EPS of $0.08 (Dec 21).

Ikena Oncology Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
STTK	Shattuck Labs	$1.11	$12.00	981.08%	Hold
XLO	Xilio Therapeutics	$0.94	$7.00	644.68%	Buy
HOWL	Werewolf Therapeutics	$1.64	$12.00	631.71%	Buy
AVTE	Aerovate Therapeutics	$2.66	$13.00	388.72%	Hold
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
STOK	Stoke Therapeutics	$11.31	$30.60	170.56%	Buy
RZLT	Rezolute	$5.01	$13.50	169.46%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
CELC	Celcuity	$12.78	$31.50	146.48%	Buy
FHTX	Foghorn Therapeutics	$7.86	$16.33	107.76%	Buy
DSGN	Design Therapeutics	$5.48	$9.67	76.46%	Buy
NRIX	Nurix Therapeutics	$22.64	$32.20	42.23%	Buy
EWTX	Edgewise Therapeutics	$31.95	$45.00	40.85%	Buy
KYMR	Kymera Therapeutics	$44.05	$51.50	16.91%	Buy
IKNA	Ikena Oncology	$1.70	$1.33	-21.76%	Buy

IKNA Forecast FAQ

Is Ikena Oncology a good buy?

Yes, according to 6 Wall Street analysts, Ikena Oncology (IKNA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 66.67% of IKNA's total ratings.

What is IKNA's price target?

Ikena Oncology (IKNA) average price target is $1.33 with a range of $1.33 to $1.33, implying a -21.76% from its last price of $1.7. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ikena Oncology stock go up soon?

According to Wall Street analysts' prediction for IKNA stock, the company can go down by -21.76% (from the last price of $1.7 to the average price target of $1.33), down by -21.76% based on the highest stock price target, and down by -21.76% based on the lowest stock price target.

Can Ikena Oncology stock reach $3?

IKNA's average twelve months analyst stock price target of $1.33 does not support the claim that Ikena Oncology can reach $3 in the near future.

What are Ikena Oncology's analysts' financial forecasts?

Ikena Oncology's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5M (high $5M, low $5M), average EBITDA is $-5M (high $-5M, low $-5M), average net income is $-36.354M (high $-35.829M, low $-36.879M), average SG&A $6.22M (high $6.22M, low $6.22M), and average EPS is $-0.753 (high $-0.742, low $-0.764). IKNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-24.848M (high $-24.848M, low $-24.848M), average SG&A $0 (high $0, low $0), and average EPS is $-0.515 (high $-0.515, low $-0.515).

Did the IKNA's actual financial results beat the analysts' financial forecasts?

Based on Ikena Oncology's last annual report (Dec 2022), the company's revenue was $15.62M, which missed the average analysts forecast of $18.78M by -16.85%. Apple's EBITDA was $-70.153M, beating the average prediction of $-28.738M by 144.11%. The company's net income was $-66.626M, missing the average estimation of $-69.244M by -3.78%. Apple's SG&A was $22.2M, missing the average forecast of $23.36M by -4.98%. Lastly, the company's EPS was $-1.84, beating the average prediction of $-1.546 by 19.05%. In terms of the last quarterly report (Dec 2023), Ikena Oncology's revenue was $659K, missing the average analysts' forecast of $2.44M by -72.98%. The company's EBITDA was $-21.603M, beating the average prediction of $-2.438M by 785.91%. Ikena Oncology's net income was $-19.489M, missing the average estimation of $-20.085M by -2.97%. The company's SG&A was $8.29M, beating the average forecast of $3.03M by 173.40%. Lastly, the company's EPS was $-0.41, missing the average prediction of $-0.416 by -1.49%